WS #16628
Corporate earnings and guidance remain a secondary focus amidst the macro turmoil. MasTec reported a record $24.5B backlog, while BP outlined $33B-$35B in financial obligations. OmniAb provided a revenue outlook backed by an Eli Lilly deal. These updates are largely overshadowed by the broader tech selloff and geopolitical risks, but they provide insight into specific sector dynamics.
Corporate Earnings and Guidance
Corporate earnings and guidance remain a secondary focus amidst the macro turmoil. MasTec reported a record $24.5B backlog, while BP outlined $33B-$35B in financial obligations. OmniAb provided a revenue outlook backed by an Eli Lilly deal. These updates are largely overshadowed by the broader tech selloff and geopolitical risks, but they provide insight into specific sector dynamics.